Bruker-Novacyt, PerkinElmer launch COVID-19 diagnostics; plus Nuclein speeds development its PCR test

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

New COVID-19 diagnostics were launched in Europe and the U.S. on Tuesday, while another company is speeding up development of an PCR self-test.

Bruker Corp. (NASDAQ:BRKR) announced the European launch of a COVID-19 test from Primerdesign Ltd., a Novacyt S.A. (LSE:NCYT; Euronext:ALNOV) subsidiary. The real-time PCR test from Primerdesign’s genesig platform is to be used in conjunction with the GenoXtract automated genome extraction device and associated kits from Bruker subsidiary Bruker-Hain Diagnostics. Bruker has distribution rights for the PCR test, which has a CE-IVD mark.

Stateside, FDA granted an emergency use authorization (EUA) to PerkinElmer Inc. (NYSE:PKI) for its New Coronavirus RT-PCR test. CLIA-certified labs may run the test.

Additionally, Nuclein LLC announced plans to accelerate development and commercialization of its Hand-Held PCR Test, which would give results within one hour. The diagnostic, in conjunction with telemedicine, could be used as a self-test. The company plans to launch the test by fall 2020.

Further analysis of the coronavirus crisis can be found at

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers